Author
Alessandro Granito
Other affiliations: University of Milan
Bio: Alessandro Granito is an academic researcher from University of Bologna. The author has contributed to research in topics: Hepatocellular carcinoma & Sorafenib. The author has an hindex of 44, co-authored 150 publications receiving 6427 citations. Previous affiliations of Alessandro Granito include University of Milan.
Papers published on a yearly basis
Papers
More filters
University of Barcelona1, University of Bologna2, Taipei Veterans General Hospital3, Chiba University4, Pierre-and-Marie-Curie University5, University of Cambridge6, Tianjin Medical University7, University of Lorraine8, Kindai University9, National Taiwan University10, Catalan Institution for Research and Advanced Studies11, Icahn School of Medicine at Mount Sinai12, University of California, Los Angeles13, Bayer Corporation14, Bayer15, Bayer HealthCare Pharmaceuticals16, Fourth Military Medical University17
TL;DR: Regorafenib is the only systemic treatment shown to provide survival benefit in HCC patients progressing on sorafenIB treatment, and future trials should explore combinations of regorAFenib with other systemic agents and third-line treatments for patients who fail or who do not tolerate the sequence of sorafanib and regorafinib.
2,543 citations
University of California, Los Angeles1, University of Bologna2, Taipei Veterans General Hospital3, Chiba University4, Pierre-and-Marie-Curie University5, University of Florida6, Mount Sinai Hospital7, University of Kansas8, Bayer Corporation9, Bayer10, Bayer HealthCare Pharmaceuticals11, University of Barcelona12
TL;DR: Examination of characteristics and outcomes of patients with hepatocellular carcinoma who were treated with regorafenib after they had disease progression during sorafenIB treatment show that regoracenib conferred a clinical benefit regardless of the last sorafanib dose or TTP on prior sorafinib.
259 citations
TL;DR: Serum IgA-TTG measurement is effective and at least as good as IgA -EMA in the identification of coeliac disease and should not depend only on biopsy, but in addition the clinical picture and serology should be considered.
Abstract: Antiendomysial and antihuman recombinant tissue transglutaminase antibodies in the diagnosis of coeliac disease : a biopsy-proven European multicentre study.
212 citations
TL;DR: It is demonstrated that the refined definition of the typical contrast enhanced ultrasound pattern of HCC introduced by the Liver Imaging Reporting and Data System (LI-RADS) practically abolishes the risk of misdiagnosis of other malignant entities (e.g. cholangiocarcinoma) for HCC with negligible reduction in sensitivity.
170 citations
TL;DR: The data show that the defect in immunoregulation in adult AIH is complex, and γδ T cells are likely to be effectors of liver damage.
161 citations
Cited by
More filters
TL;DR: The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.
7,851 citations
01 Jan 2020
TL;DR: Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future.
Abstract: Summary Background Since December, 2019, Wuhan, China, has experienced an outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Epidemiological and clinical characteristics of patients with COVID-19 have been reported but risk factors for mortality and a detailed clinical course of illness, including viral shedding, have not been well described. Methods In this retrospective, multicentre cohort study, we included all adult inpatients (≥18 years old) with laboratory-confirmed COVID-19 from Jinyintan Hospital and Wuhan Pulmonary Hospital (Wuhan, China) who had been discharged or had died by Jan 31, 2020. Demographic, clinical, treatment, and laboratory data, including serial samples for viral RNA detection, were extracted from electronic medical records and compared between survivors and non-survivors. We used univariable and multivariable logistic regression methods to explore the risk factors associated with in-hospital death. Findings 191 patients (135 from Jinyintan Hospital and 56 from Wuhan Pulmonary Hospital) were included in this study, of whom 137 were discharged and 54 died in hospital. 91 (48%) patients had a comorbidity, with hypertension being the most common (58 [30%] patients), followed by diabetes (36 [19%] patients) and coronary heart disease (15 [8%] patients). Multivariable regression showed increasing odds of in-hospital death associated with older age (odds ratio 1·10, 95% CI 1·03–1·17, per year increase; p=0·0043), higher Sequential Organ Failure Assessment (SOFA) score (5·65, 2·61–12·23; p Interpretation The potential risk factors of older age, high SOFA score, and d-dimer greater than 1 μg/mL could help clinicians to identify patients with poor prognosis at an early stage. Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future. Funding Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences; National Science Grant for Distinguished Young Scholars; National Key Research and Development Program of China; The Beijing Science and Technology Project; and Major Projects of National Science and Technology on New Drug Creation and Development.
4,408 citations
Kindai University1, University of California, Los Angeles2, Yonsei University3, University of Bologna4, California Pacific Medical Center5, Fourth Military Medical University6, Gdańsk Medical University7, University of Bordeaux8, Hannover Medical School9, Beatson West of Scotland Cancer Centre10, Eisai11, National Taiwan University12
TL;DR: Lenvatinib was non-inferior to sorafenib in overall survival in untreated advanced hepatocellular carcinoma and the safety and tolerability profiles of lenvatinIB were consistent with those previously observed.
3,046 citations
University of Navarra1, University of Hong Kong2, Kindai University3, National Taiwan University4, Seoul National University Hospital5, Goethe University Frankfurt6, University of Michigan7, Royal Free Hospital8, Asan Medical Center9, The Chinese University of Hong Kong10, Johns Hopkins University11, Bristol-Myers Squibb12, Chartered Institute of Management Accountants13
TL;DR: Durable objective responses show the potential of nivolumab for treatment of advanced hepatocellular carcinoma, and safety and tolerability for the escalation phase and objective response rate were primary endpoints.
2,908 citations
TL;DR: This paper aims to demonstrate the efforts towards in-situ applicability of EMMARM, as to provide real-time information about concrete mechanical properties such as E-modulus and compressive strength.
2,734 citations